XTL Biopharmaceuticals Ltd. — M&A Activity 2009

Jan 28, 2009

_________ false

C003��� �� �� ������������� ��"�2PublicX T L BIOPHARMACEUTICALS LTD4313Corporation no: 520039470Stock Exchange/Market: ��� �� ��1996381Hasapir 3 , Nes Ziona 76100 , ,Tel: 08-9304444 , Fax: 08-9304445E.mail address: rcohen@xtlbio.comDate of transmission: 28/01/2009              Time of broadcast: 11:29 11:28:55

Reference: 2009-02-024219

Israel Securities Authority		Tel Aviv Stock Exchange
www.isa.gov.il		www.tase.co.il

Other Report or AnnouncementRegulation 5 of the Securities Regulations, (Periodic and Immediate Reports of Foreign Corporation) 5761-2000 The corporation is a foreign private issuer as defined by U.S. Securities Laws.

Attached hereto is a report on	Company announced an update to its December 8, 2008 press release regarding the Company's activities in seeking to acquire potential assets or to identify a company to merge into or with XTL

XTLUpdateJan09final_isa.pdf

References of previous documents relating to this matter(the reference does not constitute incorporation by reference):
Previous names of reporting entity: XENOGRAFT TECHNOLOGIES LTD
Date of revision of form structure: 31/12/2008
- - -
Name of the Signatory: : Kantor Ronen , Position of Signatory in the reporting corporation: Legal Consultant & Corporate Secretary , Name of Employer Company: .
Abba Hillel Silver Telephone: 03-6133371 , Facsimile: 03-6133372 , E-mail: rkantor@kantor-law.com 2